Clinical Trials Browser

Interventional × Recurrent Squamous Cell Lung Carcinoma × Docetaxel × Clear all

NCT02766335 2023-05-25

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 2/3 Completed

116 enrolled 23 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02536495 2015-10-30

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Phase 1/2 Withdrawn

Recurrent Squamous Cell Lung Carcinoma